

Clinical Significance of microRNA Polymorphisms and Expression Profiles in Oral Cancer Development

Kaiser Jamil*

Head of Genetics Department, Bhagwan Mahavir Medical Research Centre, AC Guards, Hyderabad, Telangana, India

*Corresponding author: Kaiser Jamil, Head of Genetics Department, Bhagwan Mahavir Medical Research Centre, AC Guards, Hyderabad-500004, Telangana, India, Tel: +919849706385, E-mail: kj.bmmrc@gmail.com

Citation: Kaiser Jamil (2018) Clinical Significance of microRNA Polymorphisms and Expression Profiles in Oral Cancer Development. J Cancer Sci Clin Oncol 5(1): 104

Received Date: January 14, 2018 **Accepted Date:** June 19, 2018 **Published Date:** June 22, 2018

Abstract

MicroRNAs (miRNA) are potent regulators, controlling multiple biological processes, including cell growth, differentiation, cell death, development and immune responses. With emerging data supporting that miRNAs play a central role in gene dysregulation in human malignancies, unraveling the miRNA genetic variations in cancer is essential and critical if we want to develop better diagnostic and prognostic system for our patients. Oral cancer may have a unique miRNA profiles in different cancer sub-types, which in turn may play a critical role in cancer development, progression, and can therefore be useful for cancer diagnosis and prognosis. Based on our findings and reviewing current literature, this article presents some of the miRNA expression profiles of different cancer tumors to understand its functional relevance and its genetic polymorphism with the oral risk of cancer.

Keywords: miRNAs; Cancer; Polymorphism; Genetic Variations; Clinical Significance.

Introduction

Head and neck cancers are the sixth most prevalent and, many a times, most preventable type of cancer in the world and one of the leading causes of death in developing countries [1,2]. Among them, oral cancer is most common worldwide with a predicted 275,000 new cases each year [3]. Global statistics indicate that people in the South Asian region, including India, are particularly affected with oral cancer, ranking either first or second, among the different types of cancer prevalence in these countries [4,5]. This could be due to their smoking or/and drinking habits plus their economic status. Perhaps, the two greatest health concerns worldwide at present are cancer and smoking, both of which are continuously rising in incidence and are associated with high morbidity and mortality. Understanding the aetiology and mechanisms of these diseases is critical for developing clear and effective strategies for improving global health [6]. Many studies have also shown that cancer is not only related to environmental factors, but also to individuals' genetic susceptibility (predisposition) [7-10]. Further, Ambrose *et al.* proposed a new mechanism of microRNA(miRNA)-mediated transcriptional regulation that could promote cancer development [11]. miRNA has been another hotspot in cancer research in recent years [12,13]. Most miRNAs reside within intergenic or intronic regions of other genes. They are non-coding, single stranded RNAs of ~22 nucleotides and negatively regulate their target mRNAs at the post transcriptional level [14-16].

MicroRNA Biogenesis

miRNAs are single strands of 18-22 nucleotides in size and serve as very important regulators of gene expression at the post-transcriptional level. The biogenesis or the processing of miRNA is a two-step procedure and takes place in both nucleus and cytoplasm [17] (Figure 1).

In the nucleus, a large precursor RNA known as a pri-miRNA is transcribed by the RNA polymerase II enzyme. The pri-miRNA is processed by the RNase III enzyme, Drosha, into a ~70-nucleotide pre-miRNA. The pre-miRNA is exported from the nucleus to the cytoplasm by the RAN GTP-dependent transporter exportin 5 (XPO5). In cytoplasm, the pre-miRNA is further processed into a double-stranded RNA of ~22 nucleotides-miRNA: miRNA* duplex by another RNase III enzyme, Dicer. Finally, one strand of the duplex is incorporated into the RNA induced silencing complex (RISC) that is composed of the Argonaute proteins, Gemin3 and Gemin4 and others; and the target mRNA will be degraded or repressed for the translation depending on the degree of the complementarity of the miRNA to its target sequences. So far, miRNAs have been identified to regulate one third of human mRNA expression, and impact various genetic pathways including carcinogenesis-

related pathways; thus, it is possible that the disrupted function of miRNAs may contribute to diverse diseases, including cancer [18-21]. Also, miRNAs themselves can be oncogenic or tumor suppressing [22,23].




Figure 1: Overview of miRNA biogenesis

Genetic Variations in miRNAs

The binding of miRNA to mRNA is critical for regulating the mRNA level and protein expression. However, this binding can be affected by single-nucleotide polymorphisms that can reside in the miRNA target site, which can either abolish existing binding sites or create illegitimate binding sites. Therefore, polymorphisms in miRNA can have a differing effect on gene and protein expression and represent another type of genetic variability that can influence the risk of certain human diseases. The increase or decrease in miRNA binding caused by the variations would probably lead to a corresponding decrease or increase in protein translation.

To date, more than 2500 miRNA molecules have been identified in the human genome and they play important roles in a broad range of physiological and pathological processes and miRNAs are proposed to influence gene expression of 30% of protein-coding genes [24]. Recent studies have also implicated miRNAs in the genesis, progression and prognosis of multiple human malignancies [22,23,25-29]. Up and down regulation in the level of expression of distinct miRNAs have been observed to be associated in the development and progression of cancer. It is therefore possible that variations in miRNA expression may promote carcinogenesis by modulating the expression patterns of essential genes involved in tumor growth and progression and suppressing the functions of tumor suppressor genes.

Aberrant miRNA expression in malignant cells may occur due to alterations in variations in copy numbers and amplification, deletion or translocation of genes, or loss of heterozygosity of tumor suppressor genes. Deregulation of transcription factors (eg., p53, c-Myc) that control expression of miRNAs may result in increased cell cycling, for instance via promoting progression from G1 to S phase, thus aiding proliferation of cancer cells. Epigenetic alterations such as DNA methylation and histone acetylation of miRNAs that function in tumor suppression may lead to their inactivation, thus promoting carcinogenesis [20,21,30].

There are several mechanisms through which miRNAs function in carcinogenesis. miRNAs function in several crucial cell

growth pathways, and their dysregulation contributes to hindering growth suppressors and increased cancer cell proliferation. miRNA may also aid in circumvention of apoptotic signaling, leading to increased cancer cell growth. miRNAs may also function in epithelial-mesenchymal transition and cancer metastasis, through loss of cell adhesion and activation of genes that promote tumor cell motility and invasion. miRNAs that target angiogenesis signaling pathways may aid hypoxia in the tumor microenvironment, contributing to the maintenance of cancer cells [20,21].

Since most of the miRNA genes are found to be located in cancer-related chromosomal regions functioning either as oncogenes or tumor suppressor genes; single nucleotide polymorphisms (SNPs) in these genes could therefore be the most common form of variations present in the human genome.

It is widely accepted that SNPs are associated with cancer risk. SNPs occurring in miRNA sequences can affect processing and binding ability of mature miRNA associated with susceptibility to different cancers [27-29]. As miRNAs have a widespread effect on mRNA transcripts, a description of human natural variation associated with the miRNA system is warranted for understanding its functional and evolutionary significance. Technologies and new methodologies have helped us to identify miRNAs and their binding sites (i.e., targets) [31-33]. Table 1 presents an overview of some of the experimental and computational methods used for identification of miRNAs and their targets. The availability of comprehensive genomic databases of SNPs provides an unprecedented opportunity to explore human evolution at miRNAs levels and their targets. Recent knowledge on miRNA target genes indicates their involvement in cell proliferation, differentiation and apoptosis [19,53].

S.No.	Method	Experimental/ Computational	Reference
1.	Expression Profiling using by microarray, high-throughput sequencing, or proteomics	Experimental	[34]
2.	Polysome Profiling by high-throughput sequencing	Experimental	[35]
3.	Pull-Down Assays (eg., Labeled microRNA pull-down assay, Immunoprecipitation), followed by microarray or high-throughput sequencing	Experimental	[36-41]
4.	MiRscan http://genes.mit.edu/mirscan/	Computational	[42,43]
5.	TargetScan http://www.targetscan.org/	Computational	[44]
6.	TargetScanS http://genes.mit.edu/tscan/targetscanS2005.html	Computational	[45]
7.	RNA22 http://cm.jefferson.edu/rna22v1.0/	Computational	[46]
8.	PITA http://genie.weizmann.ac.il/pubs/mir07/	Computational	[47]
9.	RNAhybird http://bibiserv.techfak.uni-bielefeld.de/rnahybrid/submission.html	Computational	[48]
10.	DIANA-microT http://diana.imis.athena-innovation.gr/DianaTools/index.php?r=microT_CDS/index	Computational	[49,50]
11.	ToppMiR https://toppmir.cchmc.org/	Computational	[51]
12.	MiRNet http://www.mirnet.ca	Computational	[52]

Table 1: Experimental and computational methods used for identification of miRNAs and their targets

Over the past few years, several reports have shown that genetic variations in the precursor of miRNAs (pre-miRNAs) affect maturation/expression of respective mature miRNA and have been studied in several cancers including carcinoma of the breast, urinary bladder, cervical, head and neck, gastric, and lung. Jeon *et al.* reported that pre-miR-146a may contribute to genetic susceptibility in lung cancer, and that miR-146a might be involved in the progress of lung cancer development [26]. Shen *et al.* reported that CC genotype of miR-196a2 rs11614913 was associated with an increased esophageal squamous cell carcinoma risk while Wei *et al.* reported that the functional polymorphism in miR-196a2 rs11614913 T>C might contribute to decreased esophageal squamous cell carcinoma risk among women patients [27,28]. A meta-analysis study by Xu *et al.* has clarified that three common polymorphisms in microRNAs, miR-146aG>C, miR-196a2C>T, miR-499A>G, have different effects on cancer risk in the Asian population [29]. Previous studies showed that polymorphism in miRNA can change the expression of mature miRNAs or the binding activities to target mRNA, and thus influence cancer risk through various mechanisms and may also lead to chemoresistance [54-56]. Several authors have reported that genetic variations in miRNA are susceptible to breast cancer [57-60]. Umar, *et al.* reported that pre-miRNA polymorphisms cumulatively affected the susceptibility and survival of

esophageal cancer patients in north Indian population [61].

These reports support the exploration of miR-196a2 as a therapeutic target in cancers, especially in oral cancers. We have conducted genetic studies of miRNA SNPs in oral cancers and have demonstrated the key role of a few miRNAs (miR-196a2C>T and miR-149C>T) and their associated risk of oral cancers [23,62]. We found that the CC genotype of both the miRNAs were associated strongly with risk of development of oral cancers. Our epidemiological studies have demonstrated the association of SNPs in miRNAs with cancer susceptibility. A study by Hoffman *et al.* has shown that polymorphism in miR-499 influences the expression levels of miR-499a-5p during the tumorigenesis of oral squamous cell carcinoma [63]. Increased expression of miR-21 may aid in invasion, while upregulation of miR-31 may aid in increased proliferation, migration, and epithelial-mesenchymal transition in oral squamous cell carcinoma [64,65]. Overexpression and rs2910164 polymorphism in miR-146a have been implicated in progression of oral squamous cell carcinoma, though further studies have been suggested to confirm their role [66-68]. Increased expression of miR-155 and miR-27a were suggested to play a role in the progression of tumorigenesis of oral squamous cell carcinoma miR-27a may downregulate *MCPH1*, a tumor suppressor gene and thus promote carcinogenesis [69-70]. Few studies have reported that downregulation of tumor suppressor miRNAs may aid in oncogenesis of oral squamous cell carcinoma; for instance, downregulation of miR-1 has recently been suggested to promote increases metastasis and invasion in oral squamous cell carcinoma [71]. In another instance decreased expression of miR-99a was found to be associated with increased proliferation and survival of oral squamous cell carcinoma cells and could serve as a potential therapeutic target or as a biomarker [72]. A study by Uesugi *et al.* suggests that epigenetic silencing of miR-218 through hypermethylation may promote carcinogenesis in oral squamous cell carcinoma through activation of the mTOR-Akt signaling pathway [73]. In addition, miR-17/20a, miR-125b, miR-155, miR-181 and miR-491-5p are associated with poor patient survival in oral squamous cell carcinoma [74-78]. These findings suggest that miRNAs may be explored as prognostic and diagnostic markers in oral squamous cell carcinoma.

MiRNAs play critical roles in key cellular processes such as cell growth and differentiation,. Hence, their aberrant functioning due to alterations in their expression and/or polymorphisms in their target sites leads to altered cell cycle, loss of genome integrity and stress response, inhibition of apoptosis and promotion of metastasis in various cancers, supporting their exploration as clinical markers [23-29, 55-79]. Previous studies in other cancers from Indian population reported that polymorphisms in miRNA-related genes might alter the expression levels of mature miRNAs, with consequences on the regulation of target genes that affect cancer risk or prognosis [23,61,62]. On the other hand, gaining better insight into the regulatory mechanisms of microRNA would allow us to design new therapeutic regime, which may target the disease with better outcome for suffering patients. RNAi has also been suggested as novel therapeutic platform technology for oncological solutions [80]. However, several of the mechanisms proposed for the biogenesis or processing of miRNAs and their expressions are mostly based on animal model studies or in vitro studies, except a few recent studies which relate to human disease state; hence this topic remains a subject for future investigations.

Acknowledgements

My special thanks to Ms. P. Sushma who has immense interest in this work and Dr. Archana Jayaraman for useful suggestions throughout the manuscript.

References

1. Ma J, Liu Y, Yang X, Zhang CP, Zhang ZY, et al. (2013) Induction chemotherapy in patients with resectable head and neck squamous cell carcinoma: a meta-analysis. *World J Surg Oncol* 11: 67.
2. Upreti D, Pathak A, Kung SK (2014) Lentiviral vector-based therapy in head and neck cancer (Review). *Oncol Lett* 7: 3-9.
3. Warnakulasuriya S (2009) Global epidemiology of oral and oropharyngeal cancer. *Oral Oncol* 45: 309-16.
4. United Nations Statistics Division (2013) Standard Country and Area Codes Classification. USA.
5. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. *CA Cancer J Clin* 61: 69-90.
6. Jamil K (2012) Cancer communications for the development of personalized medicine. *J Solid Tumors* 2: 1-3.
7. Pérez-Losada J, Castellanos-Martín A, Mao JH (2011) Cancer evolution and individual susceptibility. *Integr Biol (Camb)* 3: 316-28.
8. Esteban-Jurado C, Garre P, Vila M, Lozano JJ, Pristoupilova A, et al. (2014) New genes emerging for colorectal cancer predisposition. *World J Gastroenterol* 20:1961-71.
9. Cerhan JR, Slager SL (2015) Familial predisposition and genetic risk factors for lymphoma. *Blood* 126: 2265-73.
10. Petridis C, Brook MN, Shah V, Kohut K, Gorman P, et al. (2016) Genetic predisposition to ductal carcinoma in situ of the breast. *Breast Cancer Res* 18: 22.
11. Ambros V (2004) The functions of animal microRNAs. *Nature* 431: 350-5.
12. Shah MY, Calin GA (2014) MicroRNAs as therapeutic targets in human cancers. *Wiley Interdiscip Rev RNA* 5: 537-48.
13. Andrés-León E, Cases I, Alonso S, Rojas AM (2017) Novel miRNA-mRNA interactions conserved in essential cancer pathways. *Sci Rep* 7: 46101.
14. Lin SL, Miller JD, Ying SY (2006) Intronic microRNA (miRNA). *J Biomed Biotechnol* 2006: 26818.
15. Hinske LC, Galante PA, Kuo WP, Ohno-Machado L (2010) A potential role for intragenic miRNAs on their hosts' interactome. *BMC Genomics* 11: 533.
16. Olena AF, Patton JG (2010) Genomic organization of microRNAs. *J Cell Physiol* 222: 540-5.

17. Jamil K (2007) MiRNAs Rewrite the rules of molecular biology. *Res J Biotech* 2: 3-5.
18. Jackson RJ, Standart N (2007) How do microRNAs regulate gene expression? *Sci STKE* 2007: re1.
19. Wang Y, Li X, Hu H (2011) Transcriptional regulation of co-expressed microRNA target genes. *Genomics* 98: 445-52.
20. Jansson MD, Lund AH (2012) MicroRNA and cancer. *Mol Oncol* 6: 590-610.
21. Peng Y, Croce CM (2016) The role of MicroRNAs in human cancer. *Signal Transduct Target Ther* 1: 15004.
22. Liu X, Chen Z, Yu J, Xia J, Zhou X (2009) MicroRNA profiling and head and neck cancer. *Comp Funct Genomics* 2009: 837514.
23. Sushma PS, Jamil K, Kumar PU, Satyanarayana U, Ramakrishna M, et al. (2015) Genetic variation in microRNAs and risk of oral squamous cell carcinoma in South Indian population. *Asian Pac J Cancer Prev* 16: 7589-94.
24. Kim VN (2005) MicroRNA biogenesis: coordinated cropping and dicing. *Nat Rev Mol Cell Biol* 6: 376-85.
25. Garzon R, Croce CM (2011) MicroRNAs and cancer: Introduction. *Semin Oncol* 38: 721-3.
26. Jeon HS, Lee YH, Lee SY, Jang JA, Choi YY, et al. (2014) A common polymorphism in pre-microRNA-146a is associated with lung cancer risk in a Korean population. *Gene* 534: 66-71.
27. Shen F, Chen J, Guo S, Zhou Y, Zheng Y, et al. (2015) Genetic 212 variants in mir-196a2 and mir-499 are associated with susceptibility to esophageal squamous cell carcinoma in Chinese Han population. *Tumour Biol* 37: 4777-84.
28. Wei J, Zheng L, Liu S, Yin J, Wang L, et al. (2013) MiR-196a2 rs11614913 T > C polymorphism and risk of esophageal cancer in a Chinese population. *Hum Immunol* 74: 1199-1205.
29. Xu Y, Gu L, Pan Y, Li R, Gao T, et al. (2013) Different effects of three polymorphisms in MicroRNAs on cancer risk in Asian population: evidence from published literatures. *PloS One* 8: e65123.
30. Hayes J, Peruzzi PP, Lawler S (2014) MicroRNAs in cancer: biomarkers, functions and therapy. *Trends Mol Med* 20: 460-9.
31. Martinez-Sanchez A, Murphy CL (2013) MicroRNA Target identification-experimental approaches. *Biology (Basel)* 2(1): 189-205.
32. Liu B, Li J, Cairns MJ (2014) Identifying miRNAs, targets and functions. *Brief Bioinform* 15: 1-19.
33. Chaudhuri K, Chatterjee R (2007) MicroRNA detection and target prediction: integration of computational and experimental approaches. *DNA Cell Biol* 26: 321-37.
34. Thomas M, Lieberman J, Lal A (2010) Desperately seeking microRNA targets. *Nat Struct Mol Biol* 17: 1169-74.
35. Ingolia NT, Ghaemmaghami S, Newman JR, Weissman JS (2009) Genome-wide analysis in vivo of translation with nucleotide resolution using ribosome profiling. *Science* 324: 218-23.
36. Hsu RJ, Tsai HJ (2011) Performing the Labeled microRNA pull-down (LAMP) assay system: an experimental approach for high-throughput identification of microRNA-target mRNAs. *Methods Mol Biol* 764: 241-7.
37. Keene JD, Komisarow JM, Friedersdorf MB (2006) RIP-Chip: the isolation and identification of mRNAs, microRNAs and protein components of ribonucleoprotein complexes from cell extracts. *Nat Protoc* 1: 302-7.
38. Baroni TE, Chittur SV, George AD, Tenenbaum SA (2008) Advances in RIP-chip analysis : RNA-binding protein immunoprecipitation-microarray profiling. *Methods Mol Biol* 419: 93-108.
39. Karginov FV, Conaco C, Xuan Z, Schmidt BH, Parker JS, et al. (2007) A biochemical approach to identifying microRNA targets. *Proc Natl Acad Sci USA* 104: 19291-6.
40. Tan LP, Seinen E, Duns G, de Jong D, Sibon OC, et al. (2009) A high throughput experimental approach to identify miRNA targets in human cells. *Nucleic Acids Res* 37: e137.
41. Chi SW, Zang JB, Mele A, Darnell RB (2009) Argonaute HITS-CLIP decodes microRNA-mRNA interaction maps. *Nature* 460: 479-86.
42. Lim LP, Lau NC, Weinstein EG, Abdelhakim A, Yekta S, et al. (2003) The microRNAs of *Caenorhabditis elegans*. *Genes Dev* 17: 991-1008.
43. Lim LP, Glasner ME, Yekta S, Burge CB, Bartel DP (2003) Vertebrate microRNA genes. *Science* 299: 1540.
44. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB (2003) Prediction of mammalian microRNA targets. *Cell* 115: 787-98.
45. Lewis BP, Burge CB, Bartel DP (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. *Cell* 120: 15-20.
46. Miranda KC, Huynh T, Tay Y, Ang YS, Tam WL, et al. (2006) A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. *Cell* 126: 1203-17.
47. Kertesz M, Ivovino N, Unnerstall U, Gaul U, Segal E (2007) The role of site accessibility in microRNA target recognition. *Nat Genet* 39: 1278-84.
48. Rehmsmeier M, Steffen P, Hochsmann M, Giegerich R (2004) Fast and effective prediction of microRNA/target duplexes. *RNA* 10: 1507-17.
49. Reczko M, Maragkakis M, Alexiou P, Grosse I, Hatzigeorgiou AG (2012) Functional microRNA targets in protein coding sequences. *Bioinformatics* 28: 771-6.
50. Paraskevopoulou MD, Georgakilas G, Kostoulas N, Vlachos IS, Vergoulis T, et al. (2013) DIANA-microT web server v5.0: service integration into miRNA functional analysis workflows. *Nucleic Acids Res* 41:W169-73.
51. Wu C, Bardes EE, Jegga AG, Aronow BJ (2014) ToppMiR: ranking microRNAs and their mRNA targets based on biological functions and context. *Nucleic Acids Res* 42: W107-13.
52. Fan Y, Siklenka K, Arora SK, Ribeiro P, Kimmins S, et al. (2016) miRNet - dissecting miRNA-target interactions and functional associations through network-based visual analysis. *Nucleic Acids Res* 44: W135-41.
53. Cai Y, Yu X, Hu S, Yu J (2009) A brief review on the mechanisms of miRNA regulation. *Genomics Proteomics Bioinformatics* 7: 147-54.
54. Wynendaele J, Böhnke A, Leucci E, Nielsen SJ, Lambert I, et al. (2010) An illegitimate microRNA target site within the 3' UTR of MDM4 affects ovarian cancer progression and chemosensitivity. *Cancer Res* 70: 9641-9.
55. Kwak PB, Iwasaki S, Tomari Y (2010) The microRNA pathway and cancer. *Cancer Sci* 101: 2309-15.
56. Ryan BM, Robles AI, Harris CC (2010) Genetic variation in microRNA networks: the implications for cancer research. *Nat Rev Cancer* 10: 389-402.
57. Hu Z, Liang J, Wang Z, Tian T, Zhou X, et al. (2009) Common genetic variants in premicroRNAs were associated with increased risk of breast cancer in Chinese women. *Hum Mutat* 30: 79-84.

58. Yao S, Graham K, Shen J, Campbell LE, Singh P, et al. (2013) Genetic variants in microRNAs and breast cancer risk in African American and European American women. *Breast Cancer Res Treat* 141: 447-59.
59. Qi P, Wang L, Zhou B, Yao WJ, Xu S, et al. (2015) Associations of miRNA polymorphisms and expression levels with breast cancer risk in the Chinese population. *Genet Mol Res* 14: 6289-96.
60. Chacon-Cortes D, Smith RA, Haupt LM, Lea RA, Youl PH (2015) Genetic association analysis of miRNA SNPs implicates MIR145 in breast cancer susceptibility. *BMC Med Genet* 16: 107.
61. Umar M, Upadhyay R, Prakash G, Kumar S, Ghoshal UC, et al. (2013) Evaluation of common genetic variants in pre-microRNA in susceptibility and prognosis of esophageal cancer. *Mol Carcinog* 52: E10-8.
62. Sushma PS, Jamil K, Kumar PU, Satyanarayana U, Ramakrishna M, et al. (2016) PTEN and p16 genes as epigenetic biomarkers in oral squamous cell carcinoma (OSCC): A study on South Indian population. *Tumor Biol* 37: 7625-32.
63. Hoffman AE, Zheng T, Yi C, Leaderer D, Weidhaas J, et al. (2009) microRNA miR-196a-2 and breast cancer: a genetic and epigenetic association study and functional analysis. *Cancer Res* 69: 5970-7.
64. Kawakita A, Yanamoto S, Yamada S, Naruse T, Takahashi H, et al. (2014) MicroRNA-21 promotes oral cancer invasion via the Wnt/ β -catenin pathway by targeting DKK2. *Pathol Oncol Res* 20: 253-61.
65. Liu CJ, Lin SC, Yang CC, Cheng HW, Chang KW (2012) Exploiting salivary miR-31 as a clinical biomarker of oral squamous cell carcinoma. *Head Neck* 34: 219-24.
66. Hung PS, Liu CJ, Chou CS, Kao SY, Yang CC, et al. (2013) miR-146a enhances the oncogenicity of oral carcinoma by concomitant targeting of the IRAK1, TRAF6 and NUMB genes. *PLoS One* 8: e79926.
67. Hung PS, Chang KW, Kao SY, Chu TH, Liu CJ, et al. (2012) Association between the rs2910164 polymorphism in pre-mir-146a and oral carcinoma progression. *Oral Oncol* 48: 404-8.
68. Min A, Zhu C, Peng S, Rajthala S, Costea DE, Sapkota D, et al. (2015) MicroRNAs as important players and biomarkers in oral carcinogenesis. *Biomed Res Int* 2015: 186904.
69. Ni YH, Huang XF, Wang ZY, Han W, Deng RZ, et al. (2014) Upregulation of a potential prognostic biomarker, miR-155, enhances cell proliferation in patients with oral squamous cell carcinoma. *Oral Surg Oral Med Oral Pathol Oral Radiol* 117: 227-233.
70. Venkatesh T, Nagashri MN, Swamy SS, Mohiyuddin SM, Gopinath KS, et al. (2013) Primary microcephaly gene MCPH1 shows signatures of tumor suppressors and is regulated by miR-27a in oral squamous cell carcinoma. *PLoS One* 8: e54643.
71. Peng CY, Liao YW, Lu MY, Yu CH, Yu CC, et al. (2017) Downregulation of miR-1 enhances tumorigenicity and invasiveness in oral squamous cell carcinomas. *J Formos Med Assoc* 116: 782-9.
72. Yan B, Fu Q, Lai L, Tao X, Fei Y, et al. (2012) Downregulation of microRNA 99a in oral squamous cell carcinomas contributes to the growth and survival of oral cancer cells. *Mol Med Rep* 6: 675-8.
73. Uesugi A, Kozaki K, Tsuruta T, Furuta M, Morita K, et al. (2011) The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer. *Cancer Res* 71: 5765-78.
74. Chang CC, Yang YJ, Li YJ, Chen ST, Lin BR, et al. (2013) MicroRNA-17/20a functions to inhibit cell migration and can be used a prognostic marker in oral squamous cell carcinoma. *Oral Oncol* 49: 923-31.
75. Shiiba M, Shinozuka K, Saito K, Fushimi K, Kasamatsu A, et al. (2013) MicroRNA-125b regulates proliferation and radioresistance of oral squamous cell carcinoma. *Br J Cancer* 108: 1817-21.
76. Shi LJ, Zhang CY, Zhou ZT, Ma JY, Liu Y, et al. (2015) MicroRNA-155 in oral squamous cell carcinoma: Overexpression, localization, and prognostic potential. *Head Neck* 37: 970-6.
77. Yang CC, Hung PS, Wang PW, Liu CJ, Chu TH, et al. (2011) miR-181 as a putative biomarker for lymph-node metastasis of oral squamous cell carcinoma. *J Oral Pathol Med* 40: 397-404.
78. Huang WC, Chan SH, Jang TH, Chang JW, Ko YC, et al. (2014) miRNA-491-5p and GIT1 serve as modulators and biomarkers for oral squamous cell carcinoma invasion and metastasis. *Cancer Res* 74: 751-64.
79. Srivastava K, Srivastava A (2012) Comprehensive review of genetic association studies and meta-analyses on miRNA polymorphisms and cancer risk. *PLoS One* 7: e50966.
80. Shafi G, Jamil K, Kapley A, Purohit HJ, Vamsy M Ch (2008) RNAi as a Novel therapeutic platform technology for oncological solutions. *Biotech Mol Bio Rev* 4: 55-70.

Submit your next manuscript to Annex Publishers and benefit from:

- ▶ Easy online submission process
- ▶ Rapid peer review process
- ▶ Online article availability soon after acceptance for Publication
- ▶ Open access: articles available free online
- ▶ More accessibility of the articles to the readers/researchers within the field
- ▶ Better discount on subsequent article submission

Submit your manuscript at

<http://www.annexpublishers.com/paper-submission.php>